WO2004064828A1 - 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 - Google Patents
2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 Download PDFInfo
- Publication number
- WO2004064828A1 WO2004064828A1 PCT/JP2004/000350 JP2004000350W WO2004064828A1 WO 2004064828 A1 WO2004064828 A1 WO 2004064828A1 JP 2004000350 W JP2004000350 W JP 2004000350W WO 2004064828 A1 WO2004064828 A1 WO 2004064828A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bromobenzoyl
- amino
- liquid preparation
- aqueous liquid
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Definitions
- the present invention relates to an aqueous solution containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- the present invention relates to a method for producing 2-amino-3- (4-bromobenzoyl)
- the present invention relates to an aqueous solution containing phenylacetic acid or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and an alkylaryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester.
- a benzoylphenylacetic acid derivative which includes a compound represented by the formula: and having a chemical name of 2-amino-3- (4-bromobenzoyl) phenylacetic acid (generic name: bromphenac) (Japanese Patent Application Laid-Open No. No. 3,052, corresponding US Pat. No. 4,045,576.).
- 2-Amino-3_ (4-bromobenzoyl) phenylacetic acid, its pharmaceutically acceptable salts and their hydrates are known as non-steroidal anti-inflammatory drugs, and in ophthalmology, extraocular and anterior eye It is effective against inflammatory diseases of the head (eg, blepharitis, conjunctivitis, scleritis, postoperative inflammation, etc.), and its sodium salt has been put into practical use in the form of eye drops (see “Recent New Drugs 20 0 1 ”, 2 0 1 year edition, Pharmaceutical Daily Co., Ltd., May 11, 2001, p. 27-29).
- 2-amino-3- (4-bromobenzoyl) phenylacetic acid is added with a water-soluble polymer (polyvinylpyrrolidone, polyvinyl alcohol, etc.) and sulfite (sodium sulfite, potassium sulfite, etc.).
- a water-soluble polymer polyvinylpyrrolidone, polyvinyl alcohol, etc.
- sulfite sodium sulfite, potassium sulfite, etc.
- Patent No. 29544356 (corresponding US Pat. Nos. 5,603,929, 5,653,972) include acidic ophthalmic
- a stable ophthalmic composition comprising an antibacterial high molecular weight quaternary ammonium compound and boric acid in a reagent has been reported.
- An example of an acidic ophthalmic reagent is 2-amino-3- (4-bromobenzoyl) phenylacetic acid.
- Patent No. 2,954,356 states that "benzalkonium chloride is a widely used preservative in ophthalmic solutions.
- benzalkonium chloride and other quaternary ammonium compounds are generally non-steroidal. It is considered incompatible with ophthalmic compositions of drugs with acidic groups, such as anti-inflammatory drugs.These preservatives lose their ability to function as they form complexes with charged drug compounds. " ing.
- alkylaryl polyether alcohol type polymers or polyethylene glycol fatty acid esters which can be used to stabilize aqueous liquids such as 2-amino-3- (4-bromobenzoyl) phenylacetic acid or pharmaceutically acceptable salts thereof.
- aqueous liquids such as 2-amino-3- (4-bromobenzoyl) phenylacetic acid or pharmaceutically acceptable salts thereof.
- the compound can be converted to a salt, and that the reduction of the antiseptic effect of benzalkonium chloride and other quaternary ammonium compounds is suppressed.
- DISCLOSURE OF THE INVENTION-The present invention relates to an ocular irritant containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- a preservative such as benzalkonium chloride is stable in a pH range that is not high
- an object of the present invention is to provide an
- Another object of the present invention is to provide a method for stabilizing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof in an aqueous solution. .
- Still another object of the present invention is to provide an aqueous solution containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate and a preservative thereof, especially It is an object of the present invention to provide an aqueous liquid preparation in which a decrease in the preservative efficacy of the preservative is suppressed when a quaternary ammonium salt such as shiridani benzalkonium is blended as a preservative.
- aqueous solutions of 2-amino-3- (4-1-bromobenzoyl) phenylacetic acid, a pharmaceutically acceptable salt thereof, or a hydrate thereof in an aqueous solution can be obtained, for example, Addition of alkylarylpolyether-terpolymers such as tyloxapol or polyethylene daricol fatty acid esters such as polyethylene glycol monostearate is stable in the pH range without eye irritation and is 2-amino-3- (4-bromobenzoyl).
- the present inventors have found that it is possible to suppress the aging of phenyl acetic acid over time, and that if the aqueous liquid contains a preservative, the deterioration of the preservative effect of the preservative can be suppressed over a long period of time. Was completed.
- Aqueous solution characterized by having,
- the alkylaryl polyether alcohol type polymer has a degree of polymerization of 3 ⁇ 10, alkyl has 1 to 18 carbon atoms, aryl is a phenyl residue, and polyether alcohol is represented by the formula ⁇ (CH 2 CH 2 ⁇ ) X H, wherein X is 5
- the aqueous liquid preparation according to the above (1) which represents an integer of from 100 to 100,
- the concentration of the alkylarylpolyether alcohol polymer is selected from the range of the lower limit of 0.01 wZv% and the upper limit of 0.5 wZv%.
- an aqueous solution containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof is added to an alkylaryl polyester such as tyloxapol.
- a stable aqueous solution containing phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof can be prepared.
- the aqueous liquid preparation of the present invention also has a sufficient preservative effect when a preservative is added.
- the aqueous liquid preparation of the present invention is advantageously used, for example, as ophthalmic solution for the treatment of blepharitis, conjunctivitis, scleritis, postoperative inflammation and the like.
- it can be advantageously used as a nasal drop for the treatment of, for example, allergic rhinitis and inflammatory rhinitis (eg, chronic rhinitis, hypertrophic rhinitis, nasal mushrooms, etc.).
- pharmacologically acceptable salts of 2-amino-3- (4-bromobenzoyl) phenylacetic acid include, for example, alkali metal salts such as sodium salt and potassium salt, and alkaline earth salts such as calcium salt and magnesium salt. Metal salts and the like. Of these salts, the sodium salt is particularly preferred.
- 2-Amino-3- (4-bromobenzoyl) phenylacetic acid and pharmacologically acceptable salts thereof are described in, for example, JP-A-52-23052 (corresponding US Pat. No. 4,045,576) or a method similar thereto. It can be appropriately manufactured by a method. These compounds can be obtained as their hydrates under the conditions of synthesis and recrystallization. Examples of the hydrate include a hemihydrate, a monohydrate, a 3/2 dihydrate and the like, and a trihydrate is preferable.
- the content (concentration range) of 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof is usually 0.01 w / v% to 0.5 w / v%, preferably about 0.05 w / v% to 0.2 w / v%, particularly preferably about 0.1 lw / v%, depending on the purpose of use and the degree of indication. It is preferable to increase or decrease as appropriate.
- a nonionic surfactant alkyl aryl used as a stabilizer for 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof is used.
- the alkyl number of the alkyl of the rupolyether alcohol type polymer is about 1-18.
- the aryl of the alkyl aryl polyether alcohol type polymer is preferably a phenyl residue.
- the average degree of polymerization of the polymer is preferably about 3 to 10.
- Tyloxapol having the following structure is particularly preferred.
- R (CH 2 CH 2 0) xH
- the fatty acid of the polyethylene glycol fatty acid ester of the surfactant is preferably a fatty acid having 12 to 18 carbon atoms. Specific compounds include polyethylene glycol monostearate (polyoxyl stearate 8, polyoxyl stearate 40, etc.), polyethylene glycol monolaurate, polyethylene glycol monooleate, polyethylene glycol disostearate, polyethylene glycol dilaurate, And polyethylene dalichol dioleate.
- Polyethylene glycol monostearate is preferred, and Polyoxyl 40 stearate is particularly preferred.
- Polyoxyl stearate 40 is a monostearic acid ester of a condensation polymer of ethylene oxide, represented by C 17 H 35 C ⁇ (CH 2 CH 20 ) n H, where n is about 40 nonionic surfactants It is.
- the content (concentration range) of the alkylaryl polyester alcohol type polymer varies depending on the kind of the compound used, etc., but the lower limit is about 0.01 w / v%, and the upper limit is 0.5 w / v%. It is about.
- the content (concentration range) of tyloxapol is a lower limit of about 0.01, 0.02 or 0.03 w / v%, and an upper limit of about 0.05, 0.1, 0.3 or 0.5 w / v%.
- the lower limit is about 0.02 w / v% and the upper limit is about 0.05 w / v%.
- the content (concentration range) of the polyethylenedaricol fatty acid ester varies depending on the type of the compound to be used, but the lower limit is about 02 w / v% and the upper limit is about 0.1 w / v%.
- the content (concentration range) of poly (ethylene glycol) monostearate has a lower limit of about 0.02 w / v%, an upper limit of about 0.1 w / v%, preferably a lower limit of about 0.02 w / v%, and an upper limit of about 0.2 w / v%. It is about 05w / v%.
- the mixing ratio of tyloxapol is 1 part by weight based on 1 part by weight of 2-amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt or hydrate thereof. Or about 0.2 parts by weight, upper limit about 0.5, 1, 3 or 5 parts by weight.
- the mixing ratio of polyethylene glycol monostearate is 2_amino-3- (4-bromobenzoyl) phenylacetic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- the lower limit is about 0.2 parts by weight and the upper limit is about 0.5 parts by weight.
- Examples of the preservative used in the aqueous liquid preparation of the present invention include quaternary ammonium salts such as benzalkonium chloride and benzethonium chloride, chlorhexidine dalconate, and the like, with salt benzalkonium being particularly preferred.
- the aqueous liquid preparation of the present invention may contain commonly used tonicity agents, buffers, thickeners, stabilizers, chelating agents, pH adjusters, fragrances, etc., so long as the object of the present invention is not adversely affected. May be appropriately added.
- the tonicity agent include sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, sucrose, propylene glycol and the like.
- the buffer include phosphate buffer, borate buffer, citrate buffer, tartaric acid buffer, acetate buffer, boric acid, borax, amino acid and the like.
- Examples of the thickening agent include polyvinyl bi-lidone, carboxymethylcellulose, carboxypropylcellulose, hydroxyshethylcellulose, hydroxypropylcellulose, and hydroxypropylcellulose. Pill methyl cellulose, polyvinyl alcohol, sodium polyacrylate, and the like.
- Examples of the stabilizer include sulfites such as sodium sulfite.
- Examples of the chelating agent include sodium edetate, sodium citrate, and condensed sodium phosphate.
- Examples of the pH adjuster include hydrochloric acid, sodium hydroxide, phosphoric acid, and acetic acid.
- Examples of fragrances include 1-menthol, polneol, camphor, eucalyptus oil and the like.
- the concentration of each of the above additives to be added to the aqueous liquid preparation of the present invention is, for example, that the tonicity agent is added to a concentration at which the osmotic pressure ratio becomes about 0.8 to 1.2, and the buffer is 0.01 to 0.1. About 2 w / v%, and the thickening agent is about 0.1 to 1 O w / v%.
- the pH of the aqueous liquid preparation of the present invention is adjusted to about 6 to 9, preferably about 7 to 9, and particularly preferably about 7.5 to 8.5.
- the aqueous liquid preparation of the present invention may appropriately contain other same or different kinds of pharmaceutically active ingredients as long as the object of the present invention is not adversely affected.
- the aqueous liquid preparation of the present invention can be produced by a method known per se, for example, a liquid preparation or eye drops described in the Japanese Pharmacopoeia 14th Edition, General Rules for Preparations.
- the aqueous liquid preparation of the present invention can be used for warm-blooded animals (for example, humans, rats, mice, rabbits, rabbits, bushes, dogs, cats, etc.).
- the aqueous liquid preparation of the present invention is easily produced by dissolving the above components in, for example, distilled water or sterile purified water.
- distilled water or sterile purified water For example, when used as eye drops, it can be used for inflammatory diseases of the extraocular and anterior eye areas, specifically, for example, blepharitis, conjunctivitis, scleritis, postoperative inflammation and the like.
- the dosage is, for example, 0.1-w / v% of 2-amino-3- (4-bromobenzoyl) sodium phenylacetate monohydrate.
- the frequency of administration may be increased or decreased as appropriate depending on the degree of the indication.
- the ophthalmic solution containing sodium 4-amino-3- (4-bromobenzoyl) phenyl acetate of the four formulations shown in Table 1 was prepared, filled into a polypropylene container, and tested for stability at 60 ° C.
- the residual rate (%) in Table 1 is a value corrected for the scattering of water from the container.
- ophthalmic solution containing tyloxapol, polyoxyl stearate 40, and polysorbate 80 was used in the order of 2-amino-3.
- Sodium (4-bromobenzoyl) phenylacetate was stable.
- Formula A-03 containing 0.02 w / v% of tyloxapol was more effective than Formula A-02 containing 0.15 wZv% of 2-amino-3 — (4-Bromobenzoyl) phenyl acetate was stable.
- Ophthalmic solutions containing 2-amino-3- (4-bromobenzoyl) phenyl acetic acid in the five formulations shown in Table 2 were prepared and filled in polypropylene containers. After storage at 60 ° C. for 4 weeks, the amount of 2-amino-3- (4-bromobenzoyl) phenylacetic acid in the ophthalmic solution and the pH of the ophthalmic solution were measured.
- Formulations containing% tyloxapol or 0.02, 0.05 ⁇ ⁇ % polyoxysyl stearate 40 are A-6, A-07, A-07 and A-08 0 ° (: After 4 weeks, the residual ratio of sodium 2-amino-3- (4-bromobenzoyl) phenylacetate was 90% or more, indicating sufficient stability as an ophthalmic solution. —Preservative efficacy test of aqueous solution containing sodium amino-3- (4-bromobenzoyl) phenylacetate
- Staphylococci] s aureus (hereinafter abbreviated as S. az / zrzw), Escherichia Col i (hereinafter referred to as E. col 7) for the formulations A—04, A—05, and A—07 of Experimental Example 2.
- J Pseudomonas aeruginosa (hereinafter abbreviated as P. aen / ⁇ 'ziwa); Candida albicans (hereinafter abbreviated as C. azoa.), Aspergillus niger (hereinafter abbreviated as The results were shown in Tables 3-1 and 3-2 and 3-3.
- the preservative efficacy of Formulation A-04 is based on the European Pharmacopoeia (EP) criteria A.
- EP European Pharmacopoeia
- the preservative efficacy of Formulations A-05 and A-07 was found to meet EP-B criteria (criteria B).
- EP-A standard and EP-B standard are as follows. EP—A standard;
- the number of viable bacteria of the bacterium aureus, P. aeruginosa should be less than lZl00 at 6 hours after inoculation, less than 1Z1000 at 24 hours after inoculation, and no viable bacteria should be detected after 28 days.
- the viable count of fungi (C. albicans, A. niger) must be less than lZl00 7 days after inoculation, and the same level or less after 7 days.
- the number of viable bacteria aureus, P. aeruginosa should be 1Z 10 or less 24 hours after inoculation, 1Z 1000 or less 7 days after inoculation, and the same level or less after 7 days.
- the number of viable fungi should be 1 Z 10 or less 14 days after inoculation, and the same level or less after 7 days.
- ophthalmic solution is made in the usual manner.
- the above components are used to prepare an ophthalmic solution in a conventional manner.
- the aqueous solution of the present invention is useful, for example, as an ophthalmic solution for the treatment of blepharitis, conjunctivitis, scleritis and postoperative inflammation. It is also useful as a nasal drop for the treatment of allergic rhinitis and inflammatory rhinitis (chronic rhinitis, hypertrophic rhinitis, nasal polyps, etc.).
- allergic rhinitis and inflammatory rhinitis chronic rhinitis, hypertrophic rhinitis, nasal polyps, etc.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/525,006 US8129431B2 (en) | 2003-01-21 | 2004-01-16 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
JP2005508062A JP4500261B2 (ja) | 2003-01-21 | 2004-01-16 | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
KR1020057004667A KR101059711B1 (ko) | 2003-01-21 | 2004-01-16 | 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성액제 |
DE602004013420T DE602004013420T2 (de) | 2003-01-21 | 2004-01-16 | Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure |
DE201112100019 DE122011100019I1 (de) | 2003-01-21 | 2004-01-16 | Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure. |
EP04702854A EP1586316B1 (en) | 2003-01-21 | 2004-01-16 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
HK06103637A HK1083468A1 (en) | 2003-01-21 | 2006-03-22 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid |
US13/353,653 US8497304B2 (en) | 2003-01-21 | 2012-01-19 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US13/687,242 US8669290B2 (en) | 2003-01-21 | 2012-11-28 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US14/165,976 US8754131B2 (en) | 2003-01-21 | 2014-01-28 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US14/261,720 US8871813B2 (en) | 2003-01-21 | 2014-04-25 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US14/269,692 US9144609B2 (en) | 2003-01-21 | 2014-05-05 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US14/493,903 US8927606B1 (en) | 2003-01-21 | 2014-09-23 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US14/502,014 US9561277B2 (en) | 2003-01-21 | 2014-09-30 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-12427 | 2003-01-21 | ||
JP2003012427 | 2003-01-21 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/525,006 A-371-Of-International US8129431B2 (en) | 2003-01-21 | 2004-01-16 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US10525006 A-371-Of-International | 2004-01-16 | ||
US13/353,653 Division US8497304B2 (en) | 2003-01-21 | 2012-01-19 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004064828A1 true WO2004064828A1 (ja) | 2004-08-05 |
Family
ID=32767329
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000350 WO2004064828A1 (ja) | 2003-01-21 | 2004-01-16 | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
PCT/IB2015/000887 WO2015170177A1 (en) | 2003-01-21 | 2015-05-05 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/000887 WO2015170177A1 (en) | 2003-01-21 | 2015-05-05 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Country Status (15)
Country | Link |
---|---|
US (9) | US8129431B2 (ja) |
EP (1) | EP1586316B1 (ja) |
JP (1) | JP4500261B2 (ja) |
KR (1) | KR101059711B1 (ja) |
CN (1) | CN100341498C (ja) |
AT (1) | ATE393627T1 (ja) |
BE (1) | BE2011C027I2 (ja) |
CA (2) | CA3043910A1 (ja) |
DE (2) | DE122011100019I1 (ja) |
ES (1) | ES2301964T3 (ja) |
HK (1) | HK1083468A1 (ja) |
HU (1) | HUS1100022I1 (ja) |
MX (1) | MX2016014404A (ja) |
PT (1) | PT1586316E (ja) |
WO (2) | WO2004064828A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010528014A (ja) * | 2007-05-24 | 2010-08-19 | アーシエックス セラピューティックス, インコーポレイテッド | ドライアイを処置するための処方物および方法 |
WO2012099142A1 (ja) * | 2011-01-18 | 2012-07-26 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
US8299124B2 (en) | 2004-11-05 | 2012-10-30 | Senju Pharmaceutical Co., Ltd. | Aqueous intraocular penetration-promoting eye drop |
JP2012224628A (ja) * | 2011-04-08 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | ブロムフェナク含有組成物 |
JP2013508272A (ja) * | 2009-10-15 | 2013-03-07 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 |
WO2014050301A1 (ja) * | 2012-09-27 | 2014-04-03 | 千寿製薬株式会社 | 水性液剤 |
JP2014088379A (ja) * | 2012-10-05 | 2014-05-15 | Rohto Pharmaceut Co Ltd | ブロムフェナク含有組成物 |
WO2014119642A1 (ja) * | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | 安定な水性液剤 |
WO2015046281A1 (ja) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | 安定化された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸含有水性組成物 |
JP2016500069A (ja) * | 2012-11-19 | 2016-01-07 | ボシュ・アンド・ロム・インコーポレイテッドBausch & Lomb Incorporated | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸を含有する水性液体組成物 |
JP2016117737A (ja) * | 2009-10-15 | 2016-06-30 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 |
JP2016522257A (ja) * | 2013-06-19 | 2016-07-28 | センティス リサーチ センター | 安定なブロムフェナク溶液 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552020B1 (en) * | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
DE122011100019I1 (de) | 2003-01-21 | 2011-11-03 | Senju Pharma Co | Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure. |
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
US20100130580A1 (en) * | 2006-01-25 | 2010-05-27 | Aciex Therapeutics, Inc. | Formulations and Methods for Treating Dry Eye |
JP2009524692A (ja) * | 2006-01-25 | 2009-07-02 | アーシエックス, インコーポレイテッド | ドライアイのための処方物および方法 |
BRPI0808410A2 (pt) * | 2007-02-28 | 2015-06-23 | Aciex Therapeutics Inc | Métodos e composições para normalizar secreções da glândula meibomiana |
CN101313899B (zh) * | 2007-06-01 | 2012-02-29 | 北京德众万全药物技术开发有限公司 | 一种含有溴芬酸钠的眼用药物组合物 |
CN101965183A (zh) * | 2008-02-21 | 2011-02-02 | 伊斯塔药品公司 | 作为佐剂的眼用nsaid |
EP2308466B1 (en) * | 2008-03-17 | 2017-05-31 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
US8778999B2 (en) | 2009-03-05 | 2014-07-15 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic compositions |
TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
CA2780611A1 (en) * | 2009-11-11 | 2011-05-19 | Micro Labs Limited | Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension |
US8715713B2 (en) | 2011-04-29 | 2014-05-06 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
US20130023575A1 (en) * | 2011-07-22 | 2013-01-24 | Kamran Hosseini | Compositions and methods for the treatment of ocular surface allergies |
WO2013055856A1 (en) | 2011-10-12 | 2013-04-18 | Bausch & Lomb Incorporated | Ocular composition containing bromfenac with increased bioavailability |
US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
US20130165419A1 (en) * | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
WO2014120293A1 (en) * | 2013-01-31 | 2014-08-07 | Sentiss Pharma Pvt.Ltd. | Ophthalmic formulations |
WO2014119643A1 (ja) | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | 澄明な水性液剤 |
WO2015087267A2 (en) * | 2013-12-12 | 2015-06-18 | Sentiss Pharma Private Limited | Stable bromfenac ophthalmic solution |
CN104151182B (zh) * | 2014-06-16 | 2016-03-30 | 广东众生药业股份有限公司 | 一种溴芬酸钠倍半水合物的制备方法 |
US11452732B2 (en) | 2015-09-05 | 2022-09-27 | Randal Davis | Homogeneous ophthalmic composition |
US10130639B1 (en) | 2015-09-05 | 2018-11-20 | Randal Davis | Homogeneous ophthalmic composition |
CN106404952B (zh) * | 2016-08-31 | 2019-06-11 | 辰欣佛都药业(汶上)有限公司 | 一种溴芬酸钠滴眼液有关物质的测定方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01104023A (ja) * | 1987-09-11 | 1989-04-21 | Syntex Usa Inc | 眼用保存製剤およびその製法 |
JPH02124817A (ja) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | 局所投与用炎症性疾患治療剤 |
JPH09503791A (ja) * | 1994-11-16 | 1997-04-15 | アルコン ラボラトリーズ, インコーポレイテッド | 高分子4級アンモニウム化合物を含有する保存された眼科用薬剤組成物 |
JPH11228404A (ja) * | 1997-12-11 | 1999-08-24 | Senju Pharmaceut Co Ltd | 安定な水性点眼剤 |
WO2000059475A1 (en) * | 1999-04-06 | 2000-10-12 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2880138A (en) | 1956-12-24 | 1959-03-31 | Upjohn Co | Anti-inflammatory steroid solutions |
US2880130A (en) | 1956-12-24 | 1959-03-31 | Upjohn Co | Anti-inflammatory steroid solutions |
SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
US4683242A (en) | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
US5414011A (en) | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
JPH0283323A (ja) * | 1988-09-20 | 1990-03-23 | Zeria Pharmaceut Co Ltd | 安定な酪酸リボフラビン水溶液 |
JPH02124819A (ja) | 1988-11-01 | 1990-05-14 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
JPH05223052A (ja) | 1992-02-06 | 1993-08-31 | Kanematsu Eng Kk | 波浪エネルギ−を利用した電流発生装置及びこの電流発生装置が備えられた水素ガス発生装置 |
SG49746A1 (en) | 1992-08-28 | 1998-06-15 | Pharmos Corp | Submicron emulsions as ocular drug delivery vehicles |
AU6021794A (en) | 1993-01-11 | 1994-08-15 | Allergan, Inc. | Ophthalmic compositions comprising benzyllauryldimethylammonium chloride |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
CN1091597C (zh) | 1994-03-15 | 2002-10-02 | 千寿制药株式会社 | 稳定双吡苯丙酸的方法和稳定的双吡苯丙酸液体制剂 |
ES2079320B1 (es) * | 1994-05-17 | 1996-10-16 | Cusi Lab | Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones. |
US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
WO1996011003A1 (en) | 1994-10-10 | 1996-04-18 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
US5558876A (en) * | 1995-03-29 | 1996-09-24 | Alcon Laboratories, Inc. | Topical ophthalmic acidic drug formulations |
US5750564A (en) * | 1995-09-12 | 1998-05-12 | Hellberg; Mark | Anti-oxidant esters of non-steroidal anti-inflammatory agents |
US6071904A (en) * | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
US6274592B1 (en) * | 1997-02-04 | 2001-08-14 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
US5942508A (en) * | 1997-02-04 | 1999-08-24 | Senju Pharmaceutical Co., Ltd. | Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid |
TW546151B (en) | 1997-07-23 | 2003-08-11 | Senju Pharma Co | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
US6369112B1 (en) * | 1998-12-15 | 2002-04-09 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol |
WO2001015677A2 (en) | 1999-08-31 | 2001-03-08 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
HUP0202745A2 (hu) | 1999-09-06 | 2003-01-28 | Ono Pharmaceutical Co., Ltd. | Profilaktikus és terápiás szerek szembetegségek kezelésére |
AR030345A1 (es) | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
JP2002308764A (ja) * | 2001-02-09 | 2002-10-23 | Taisho Pharmaceut Co Ltd | 眼科用医薬組成物 |
DE122011100019I1 (de) * | 2003-01-21 | 2011-11-03 | Senju Pharma Co | Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure. |
PL1683526T3 (pl) * | 2003-11-14 | 2012-09-28 | Senju Pharma Co | Preparat wodnego roztworu zawierający antybiotyk aminoglikozydowy i bromfenak |
WO2013055856A1 (en) * | 2011-10-12 | 2013-04-18 | Bausch & Lomb Incorporated | Ocular composition containing bromfenac with increased bioavailability |
AU2013344497B2 (en) * | 2012-11-19 | 2016-04-14 | Bausch & Lomb Incorporated | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
-
2004
- 2004-01-16 DE DE201112100019 patent/DE122011100019I1/de active Pending
- 2004-01-16 KR KR1020057004667A patent/KR101059711B1/ko not_active IP Right Cessation
- 2004-01-16 CN CNB2004800009763A patent/CN100341498C/zh not_active Expired - Lifetime
- 2004-01-16 PT PT04702854T patent/PT1586316E/pt unknown
- 2004-01-16 DE DE602004013420T patent/DE602004013420T2/de not_active Expired - Lifetime
- 2004-01-16 US US10/525,006 patent/US8129431B2/en active Active
- 2004-01-16 ES ES04702854T patent/ES2301964T3/es not_active Expired - Lifetime
- 2004-01-16 WO PCT/JP2004/000350 patent/WO2004064828A1/ja active IP Right Grant
- 2004-01-16 AT AT04702854T patent/ATE393627T1/de active
- 2004-01-16 JP JP2005508062A patent/JP4500261B2/ja not_active Expired - Fee Related
- 2004-01-16 EP EP04702854A patent/EP1586316B1/en not_active Expired - Lifetime
-
2006
- 2006-03-22 HK HK06103637A patent/HK1083468A1/xx not_active IP Right Cessation
-
2007
- 2007-05-30 US US11/755,662 patent/US20070287749A1/en not_active Abandoned
-
2011
- 2011-08-30 BE BE2011C027C patent/BE2011C027I2/fr unknown
- 2011-11-04 HU HUS1100022C patent/HUS1100022I1/hu unknown
-
2012
- 2012-01-19 US US13/353,653 patent/US8497304B2/en not_active Expired - Lifetime
- 2012-11-28 US US13/687,242 patent/US8669290B2/en not_active Expired - Lifetime
-
2014
- 2014-01-28 US US14/165,976 patent/US8754131B2/en not_active Expired - Lifetime
- 2014-04-25 US US14/261,720 patent/US8871813B2/en not_active Expired - Lifetime
- 2014-05-05 US US14/269,692 patent/US9144609B2/en not_active Expired - Lifetime
- 2014-09-23 US US14/493,903 patent/US8927606B1/en not_active Expired - Lifetime
- 2014-09-30 US US14/502,014 patent/US9561277B2/en not_active Expired - Lifetime
-
2015
- 2015-05-05 WO PCT/IB2015/000887 patent/WO2015170177A1/en active Application Filing
- 2015-05-05 CA CA3043910A patent/CA3043910A1/en not_active Abandoned
- 2015-05-05 MX MX2016014404A patent/MX2016014404A/es unknown
- 2015-05-05 CA CA2944832A patent/CA2944832C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01104023A (ja) * | 1987-09-11 | 1989-04-21 | Syntex Usa Inc | 眼用保存製剤およびその製法 |
JPH02124817A (ja) * | 1988-01-27 | 1990-05-14 | Senju Pharmaceut Co Ltd | 局所投与用炎症性疾患治療剤 |
JPH09503791A (ja) * | 1994-11-16 | 1997-04-15 | アルコン ラボラトリーズ, インコーポレイテッド | 高分子4級アンモニウム化合物を含有する保存された眼科用薬剤組成物 |
JPH11228404A (ja) * | 1997-12-11 | 1999-08-24 | Senju Pharmaceut Co Ltd | 安定な水性点眼剤 |
WO2000059475A1 (en) * | 1999-04-06 | 2000-10-12 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518996B2 (en) | 2004-11-05 | 2013-08-27 | Senju Pharmaceutical Co., Ltd. | Aqueous intraocular penetration-promoting eye drop |
US8299124B2 (en) | 2004-11-05 | 2012-10-30 | Senju Pharmaceutical Co., Ltd. | Aqueous intraocular penetration-promoting eye drop |
JP2010528014A (ja) * | 2007-05-24 | 2010-08-19 | アーシエックス セラピューティックス, インコーポレイテッド | ドライアイを処置するための処方物および方法 |
JP2016117737A (ja) * | 2009-10-15 | 2016-06-30 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 |
JP2018083822A (ja) * | 2009-10-15 | 2018-05-31 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 |
JP2013508272A (ja) * | 2009-10-15 | 2013-03-07 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 |
WO2012099142A1 (ja) * | 2011-01-18 | 2012-07-26 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
CN103379904A (zh) * | 2011-01-18 | 2013-10-30 | 千寿制药株式会社 | 具有保存效能的溴芬酸水性液剂组合物 |
JPWO2012099142A1 (ja) * | 2011-01-18 | 2014-06-30 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
US9107888B2 (en) | 2011-01-18 | 2015-08-18 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid bromfenac composition having preservative efficacy |
JP2012224628A (ja) * | 2011-04-08 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | ブロムフェナク含有組成物 |
WO2014050301A1 (ja) * | 2012-09-27 | 2014-04-03 | 千寿製薬株式会社 | 水性液剤 |
JPWO2014050301A1 (ja) * | 2012-09-27 | 2016-08-22 | 千寿製薬株式会社 | 水性液剤 |
JP2014088379A (ja) * | 2012-10-05 | 2014-05-15 | Rohto Pharmaceut Co Ltd | ブロムフェナク含有組成物 |
JP2016500069A (ja) * | 2012-11-19 | 2016-01-07 | ボシュ・アンド・ロム・インコーポレイテッドBausch & Lomb Incorporated | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸を含有する水性液体組成物 |
JP5753957B2 (ja) * | 2013-01-31 | 2015-07-22 | 千寿製薬株式会社 | 安定な水性液剤 |
JPWO2014119642A1 (ja) * | 2013-01-31 | 2017-01-26 | 千寿製薬株式会社 | 安定な水性液剤 |
WO2014119642A1 (ja) * | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | 安定な水性液剤 |
JP2016522257A (ja) * | 2013-06-19 | 2016-07-28 | センティス リサーチ センター | 安定なブロムフェナク溶液 |
WO2015046281A1 (ja) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | 安定化された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸含有水性組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004064828A1 (ja) | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 | |
PT2442790E (pt) | Composições aquosas farmacêuticas que contêm complexos de borato-poliol | |
US20200360326A1 (en) | Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid | |
JP5695580B2 (ja) | ラタノプロストのバイオアベイラビリティを向上させる方法 | |
WO2010120841A1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005600126 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004702854 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057004667 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525006 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048009763 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057004667 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004702854 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004702854 Country of ref document: EP |